0001193125-26-211825
SEC filingImproved operating and net losses reflect cost discipline from the wind-down of Amgen collaboration activity and lower personnel costs due to reduced headcount, partially offset by incremental stock compensation from option repricing, supporting ongoing neuroscience pipeline development.
Neumora Therapeutics reported narrower losses in Q1 FY2026, with operating income at -$52.9 million, a 25.5% improvement from -$70.9 million in the prior-year quarter. This reflects disciplined cost management, as internal and unallocated expenses decreased due to the absence of research and collaboration activity with Amgen, which had contributed costs in the prior period, alongside lower personnel-related expenses from reduced headcount and non-recurring prior bonus payments. Net income followed suit at -$53.5 million, 21.4% better than -$68.0 million year-over-year, with diluted EPS improving 28.6% to -$0.30 from -$0.42. These enhancements underscore the company's focus on operational efficiency amid its neuroscience pipeline advancement.